Publish date:

Stocks Under $10: Stealth Drug Play

Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.

David Peltier is a research associate at TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Peltier appreciates your feedback;

click here

to send him an email.

TheStreet Recommends